Small cell lung cancer

Gregory P. Kalemkerian; Wallace Akerley; Robert J. Downey; David S. Ettinger; Frank Fossella; John C. Grecula; Thierry Jahan; Bruce E. Johnson; Anne Kessinger; Marianna Koczywas; Corey J. Langer; Renato Martins; Harvey B. Niell; Charles C. Pan; Nithya Ramnath; Neal Ready; Francisco Robert; Charles C. Williams

doi:10.6004/jnccn.2008.0025

Small cell lung cancer

Gregory P. Kalemkerian, Wallace Akerley, Robert J. Downey, David S. Ettinger, Frank Fossella, John C. Grecula, Thierry Jahan, Bruce E. Johnson, Anne Kessinger, Marianna Koczywas, Corey J. Langer, Renato Martins, Harvey B. Niell, Charles C. Pan, Nithya Ramnath, Neal Ready, Francisco Robert, Charles C. Williams

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.

Original language	English (US)
Pages (from-to)	294-314
Number of pages	21
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	6
Issue number	3
DOIs	https://doi.org/10.6004/jnccn.2008.0025
State	Published - 2008
Externally published	Yes

Keywords

Carcinoma
Chemotherapy
NCCN Clinical Practice Guidelines
Pulmonary carcinogenesis
Radiotherapy
Small cell
Surgical resection

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2008.0025

Cite this

Kalemkerian, G. P., Akerley, W., Downey, R. J., Ettinger, D. S., Fossella, F., Grecula, J. C., Jahan, T., Johnson, B. E., Kessinger, A., Koczywas, M., Langer, C. J., Martins, R., Niell, H. B., Pan, C. C., Ramnath, N., Ready, N., Robert, F., & Williams, C. C. (2008). Small cell lung cancer. JNCCN Journal of the National Comprehensive Cancer Network, 6(3), 294-314. https://doi.org/10.6004/jnccn.2008.0025

Kalemkerian, GP, Akerley, W, Downey, RJ, Ettinger, DS, Fossella, F, Grecula, JC, Jahan, T, Johnson, BE, Kessinger, A, Koczywas, M, Langer, CJ, Martins, R, Niell, HB, Pan, CC, Ramnath, N, Ready, N, Robert, F & Williams, CC 2008, 'Small cell lung cancer', JNCCN Journal of the National Comprehensive Cancer Network, vol. 6, no. 3, pp. 294-314. https://doi.org/10.6004/jnccn.2008.0025

@article{75f391cfa5d747639b615a44552cd750,

title = "Small cell lung cancer",

abstract = "Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.",

keywords = "Carcinoma, Chemotherapy, NCCN Clinical Practice Guidelines, Pulmonary carcinogenesis, Radiotherapy, Small cell, Surgical resection",

author = "Kalemkerian, {Gregory P.} and Wallace Akerley and Downey, {Robert J.} and Ettinger, {David S.} and Frank Fossella and Grecula, {John C.} and Thierry Jahan and Johnson, {Bruce E.} and Anne Kessinger and Marianna Koczywas and Langer, {Corey J.} and Renato Martins and Niell, {Harvey B.} and Pan, {Charles C.} and Nithya Ramnath and Neal Ready and Francisco Robert and Williams, {Charles C.}",

year = "2008",

doi = "10.6004/jnccn.2008.0025",

language = "English (US)",

volume = "6",

pages = "294--314",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "3",

}

TY - JOUR

T1 - Small cell lung cancer

AU - Kalemkerian, Gregory P.

AU - Akerley, Wallace

AU - Downey, Robert J.

AU - Ettinger, David S.

AU - Fossella, Frank

AU - Grecula, John C.

AU - Jahan, Thierry

AU - Johnson, Bruce E.

AU - Kessinger, Anne

AU - Koczywas, Marianna

AU - Langer, Corey J.

AU - Martins, Renato

AU - Niell, Harvey B.

AU - Pan, Charles C.

AU - Ramnath, Nithya

AU - Ready, Neal

AU - Robert, Francisco

AU - Williams, Charles C.

PY - 2008

Y1 - 2008

N2 - Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.

AB - Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.

KW - Carcinoma

KW - Chemotherapy

KW - NCCN Clinical Practice Guidelines

KW - Pulmonary carcinogenesis

KW - Radiotherapy

KW - Small cell

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=41749085062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749085062&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2008.0025

DO - 10.6004/jnccn.2008.0025

M3 - Review article

C2 - 18377848

AN - SCOPUS:41749085062

SN - 1540-1405

VL - 6

SP - 294

EP - 314

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 3

ER -

Small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this